MARKET

NYMX

NYMX

Nymox
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.040
-0.030
-1.45%
Closed 16:00 09/24 EDT
OPEN
2.030
PREV CLOSE
2.070
HIGH
2.140
LOW
2.010
VOLUME
39.13K
TURNOVER
--
52 WEEK HIGH
3.500
52 WEEK LOW
1.252
MARKET CAP
160.57M
P/E (TTM)
-12.5848
1D
5D
1M
3M
1Y
5Y
BRIEF-Nymox Pharmaceutical Corp - Filed With Regulatory Bodies For Brand Names For Fexapotide
reuters.com · 09/10 13:33
NYMOX Provides Shareholder Update
 Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.   The Company
Benzinga · 09/10 13:32
Nymox Pharmaceutical Files for Regulatory Approval of Fexapotide Triflutate Brand Names
MT Newswires · 09/10 12:55
NanoVibronix, Nymox Pharmaceutical leads healthcare gainers; Sesen Bio, ESSA Pharma among major losers
Gainers: NanoVibronix NAOV +44%, Nymox Pharmaceutical (NASDAQ:NYMX) +21%, Travere Therapeutics TVTX +20%, Enlivex Therapeutics ENLV +15%, Collegium Pharmaceutical COLL +11%. Losers: Sesen Bio SESN -35%, ESSA Pharma EPIX -32%, Absci (NASDAQ:ABSI) -17%, Clev...
Seekingalpha · 08/16 15:01
BRIEF-Nymox Pharmaceutical Reports Qtrly Net Loss Per Share Basic & Diluted of $0.05
reuters.com · 08/13 18:02
BRIEF-Nymox Pharmaceutical Corp Says Quarterly Net Loss Per Share Basic & Diluted $0.05
reuters.com · 08/13 18:02
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 07/27 11:48
Who Has Been Buying Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Simply Wall St. · 07/27 07:58
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NYMX. Analyze the recent business situations of Nymox through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.12%
Pharmaceuticals & Medical Research
-1.01%
Key Executives
Chairman/Chief Executive Officer/President/Director
Paul Averback
Chief Financial Officer
Erik Danielsen
General Counsel/Director
Randall Lanham
Independent Director
Richard Cutler
Independent Director
David Morse
Independent Director
James Robinson
No Data
About NYMX
Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Webull offers kinds of Nymox Pharmaceutical Corp stock information, including NASDAQ:NYMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NYMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NYMX stock methods without spending real money on the virtual paper trading platform.